Study summary

Adding radium-223 to enzalutamide extended life for men with bone metastases

PEACE-3 trial (radium-223 plus enzalutamide) · 446 men, phase 3 · Published May 2025, Annals of Oncology

42.3months median survival, vs 35.0 with enzalutamide alone

What was tested

Enzalutamide with or without six injections of radium-223, a radioactive drug that targets bone, as first treatment for castration-resistant prostate cancer with bone metastases. Bone-protecting drugs were required.

What they found

What it means

A new combination option for bone-only or bone-predominant disease.

Ann Oncol, via PubMed ↗ Trial record NCT02194842 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.